Bitcoin eyes all-time high with 4% gap as ETFs attract massive inflows
Bitcoin’s price soared to $71,200 on Tuesday, only 4% away from its all-time high of $73,700 established earlier in March, according to data from TradingView. The rally comes on the heels of massive inflows into US spot Bitcoin exchange-traded funds (ETFs).
Data from HODL15Capital shows that US Bitcoin funds collectively witnessed $887 million in net inflows, marking the second-highest such inflow ever recorded.
US Spot
Bitcoin ETF Inflows (June 4) – Source: HODL15Capital
Leading the charge, the Fidelity Wise Origin Bitcoin Fund amassed an impressive $378 million, while BlackRock’s iShares Bitcoin Trust followed with $275 million, according to insights from Farside Investors and HODL15Capital. The ARK 21Shares Bitcoin ETF claimed the third spot with over $138 million in net inflows.
These inflows marked a significant milestone, being the most substantial since March 12, which saw a record-setting $1.04 billion influx. The following day, Bitcoin reached a peak of $73,700.
At press time, BTC is trading close to $71,000, up almost 3% in the last 24 hours. The recent surge signals a positive turn for Bitcoin after several weeks of moving sideways. Industry experts suggest that the crypto market is set for a “bright June” due to anticipated spot Ethereum ETF developments.
With Bitcoin ETFs scoring big on their 100th trading day, Nate Geraci, president of ETF Store, addressed the skepticism surrounding Bitcoin ETFs and their demand, particularly from critics who doubted their appeal to retail investors.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
